When U.S. regulators first declared COVID-19 a public health emergency — which took effect exactly six months ago — the infectious disease was deemed a low risk to the American public. Today, the known U.S. case count tops 4.3 million.

The medtech industry now has close to half a year under its belt of producing millions of diagnostic tests in addition to respiratory support devices and other equipment to help healthcare workers respond to the coronavirus. The need hasn't slowed, but unlike in March and April, much demand has also returned to many companies' traditional product lines, including for implants used in elective surgeries.

While the interest in products new and old bodes well for the sector's recovery as other industries face starker struggles, unique regulatory, supply chain and sales challenges remain.

MedTech Dive examines some of those challenges in the stories below.